Egle Therapeutics is a spin-out of Institut Curie in France, developing immunotherapies targeting suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
The key element of Egle’s core approach is the leveraging of its translational-based target discovery engine to unveil novel therapeutic Treg targets and vectorize computationally designed resurfaced cytokines acting as antagonists or as selective Treg-agonists. Egle’s flagship program pioneers dis-engagement of tumor-infiltrating Tregs through a proprietary series of IL-2 variants featuring a unique antagonism mechanism of action.
Approach: Treg immune modulation.
Indications: Oncology and autoimmune diseases.
The company has already announced a corporate strategic research alliance with Takeda with the goal of validating novel tumor-infiltrating regulatory Treg targets against which Takeda will develop potential therapies.
Egle’s flagship program focuses on the dis-engagement of tumor-infiltrating Treg through unique proprietary series of IL-2 variants that act as IL-2 antagonists.
Established in 2020, the start-up results from Eliane Piaggio’s research work, as Inserm Research Director & Head of the Translational Immunotherapy Team at Institut Curie, and Luc Boblet, a serial biotech entrepreneur.
Subscribe for alerts on new companies featured on Startups.Bio
- U-Ploid BiotechnologiesU-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility. Millions of women… Read more: U-Ploid Biotechnologies
- BioTryp TherapeuticsBioTryp Therapeutics is University of Cambridge spin-out biotechnology company that focuses on… Read more: BioTryp Therapeutics
- Bastion TherapeuticsBastion Therapeutics is a pre-clinical stage biotechnology company focused on developing best-in-class… Read more: Bastion Therapeutics
- HOVANAHOVANA is a digital biology company tackling translational dysfunction as a driver… Read more: HOVANA